Success Story: NIW and EB1-A Petition Approved for an Attending Hematologist and Oncologist from India in the Field of Medical Oncology in the gap of 1 Month only
Client’s Testimonial:
“It’s an arduous and sometimes frustrating process, but I am more than happy with the quality and professionalism of the work being put in at this firm. Thank you for being so detail-oriented, gives the applicant a lot of confidence. You guys are truly the best in the field.”
On August 20th, 2021 and September 27th, 2021, we received another EB2-NIW (National Interest Waiver) and EB-1A (Alien of Extraordinary Ability) approval for an Attending Hematologist and Oncologist in the Field of Medical Oncology (Approval Notice).
General Field: Medical Oncology
Position at the Time of Case Filing: Attending Hematologist and Oncologist
Country of Origin: India
State of Residence at the Time of Filing: Texas
Approval Notice Date: August 20th, 2021 (NIW) and September 27th, 2021 (EB-1A)
Processing Time: 10 months, 22 days (NIW) and 7 months, 30 days (EB-1A)
Case Summary:
We at North America Immigration Law Group, before moving forward with any case, take utmost care in conducting a complete background check of every client who approaches us for helping them with their immigration petition to USCIS. So, when an attending hematologist and oncologist in the field of medical oncology approached us, we made certain that he received the best legal services for his I-140 NIW (National Interest Waiver) and as well as EB-1A (Alien of Extraordinary Ability) petition.
- We delivered his exceptional professional background and unique experience important to his current and future work at the USCIS.
After reviewing his credentials, we found that our client has accumulated a splendid record of success:
- He received his MBBS from India.
- His research has resulted in 4 peer-reviewed scientific articles.
- His publications have been cited a total of 78 times in at least 16 countries according to Google Scholar.
- He has conducted at least 15 reviews for at least 3 journals.
- All the above factors thereby signify that his record of publications and citations are widely acknowledged and counted upon in the field of his expertise.
Additionally, our client’s novel lymphoma and cancer treatments research addresses some of our nation’s and the world’s most pressing issues, including HIV-related lymphoma and breast cancer. His strong background in hematology and medical oncology has allowed his research to be particularly original, resulting in his success in fundamentally transforming novel lymphoma and cancer treatments research. He is particularly well-known for his contributions to new antibody approaches to lymphoma therapy.
- Our client’s work has thus been majorly significant, and his achievements are of the utmost importance due to their direct applicability in global efforts to address the global health burdens associated with cancer and lymphoma.
Additionally, he has served as the principal investigator for the National Surgical Adjuvant Breast and Bowel Project trial consortium.
- Thus, based on the originality, practicality, and importance of our client’s research endeavors, his achievements in the academic field of research have secured his reputation as an exceptional professor in the international community of medical oncology.
Leading researchers from top universities and research groups from the United States and abroad have submitted letters confirming him as an outstanding professor in his specialized field.
- Two out of five of his recommenders have the following to say about him:
“Finally, in addition to its scholarly merit, [client’s] research is also highly beneficial to the United States…Since over 1 million Americans are living with HIV today, it can be estimated that at least 100,000 Americans suffer from HIV-related lymphoma…As these populations already receive relatively less care in the American healthcare system, there is a critical need for addressing our current lack of knowledge regarding the optimal means of preventing and treating AIDS-related lymphoma. [Client] addresses this need in his research, and his work thus directly aligns with the public health interests of the United States.”
“[Client’s] research stands at the forefront of the field of medical oncology, particularly in his research into enhanced therapies for the prevention of breast cancer…Through his innovative research on the novel use of phytochemicals to prevent breast cancer, [client] has worked to directly address this imperative. The ultimate value of his research on this topic is thus wholly incalculable.”
We are certain that he is more than capable of furthering his knowledge base in the chosen field and continuing his work in the United States of America.
- The best news is that he not only received his NIW and EB1-A approvals with the help of our firm’s continuous guidance, he even received his 1-485 application approved very recently.
We thus wish him the very best in his life and success in all the endeavors that he takes up soon.